U.S. missile stockpiles dwindle. And, FDA weighs approval of flu shots with mRNA tech
NPR World
Published
2
1
Read the full story at NPR WorldOriginal
The U.S. Army's missile stockpile is dwindling and could take years to replenish. And, the Food and Drug Administration is deciding whether to approve a flu vaccine with mRNA technology.
Related Markets
All MarketsModerna Inc.
MRNA
View full chart →
View Full Chart
Market data may be delayed. Not financial advice.
Reader Reactions
The Story At A Glance
The depletion of munitions stems from high demand during air defense operations that exceeded peacetime planning. Simultaneously, the medical establishment is attempting to expand the use of mRNA platforms beyond COVID-19.
- • U.S. missile stocks, including Patriot and THAAD interceptors, have been depleted by recent conflict with Iran.
- • Rebuilding these critical defense inventories will take between one and four years due to production constraints.
- • The FDA is currently reviewing the approval of mRNA technology for seasonal flu vaccines.
The depletion of munitions stems from high demand during air defense operations that exceeded peacetime planning. Simultaneously, the medical establishment is attempting to expand the use of mRNA platforms beyond COVID-19.
Christian Perspective
A nation that cannot defend its borders and people is failing its God-given duty to maintain order and security.
What is your reaction to this story?
Reader Reactions
Want to join the conversation about this story?
Join our community at Gab.com→
Alto is powered by
Gab AI
The one AI they can't control. Our exclusive AI model trained to uphold Christian values and traditional principles in every interaction.
